Inhibrx Biosciences (NASDAQ:INBX) Stock Jumps 8.2% - Here's What Happened

Inhibrx Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • INBX rose 8.2% to about $74.72 in Thursday trading, while volume fell 83% below its daily average.
  • A Phase 1/2 study of ozekibart in relapsed or refractory Ewing sarcoma reported a 62.7% overall response rate and an 86.3% disease-control rate; the treatment remains investigational and requires further development and regulatory review.
  • Analyst views were mixed: the consensus rating was “Moderate Buy” with an average price target of $185, while recent ratings included sell calls and HC Wainwright lowered its target to $220 but kept a Buy rating. Insiders purchased 62,540 shares over the past 90 days, compared with 1,500 shares sold.
  • MarketBeat previews the top five stocks to own by December 1st.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) rose 8.2% during trading on Thursday. The company traded as high as $74.63 and last traded at $74.7230. 51,185 shares changed hands during trading, a decline of 83% from the average daily volume of 309,527 shares. The stock had previously closed at $69.06.

Trending Headlines about Inhibrx Biosciences

Investors following INBX have been watching these headlines:

  • Positive Sentiment: In a Phase 1/2 study of ozekibart combined with irinotecan and temozolomide in relapsed or refractory Ewing sarcoma, the company reported a 62.7% overall response rate and an 86.3% disease-control rate, with durable responses in heavily pretreated patients. The findings could strengthen the drug’s prospects, but further development and regulatory review will be needed. Inhibrx clinical data announcement
  • Negative Sentiment: HC Wainwright cut its price target, according to a report, while maintaining a Buy rating and a $220 target. Its earnings revisions were mixed: the firm projected a larger 2026 loss but a smaller 2027 loss. HC Wainwright price target report

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on INBX shares. Wall Street Zen lowered shares of Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a report on Monday, August 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. HC Wainwright lowered their price objective on Inhibrx Biosciences from $245.00 to $220.00 and set a "buy" rating for the company in a report on Monday. Finally, Citigroup reiterated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $185.00.

View Our Latest Analysis on INBX

Inhibrx Biosciences Stock Up 10.5%

The firm's 50 day simple moving average is $92.72 and its 200 day simple moving average is $92.13. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -8.42 and a beta of 4.03.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($2.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.45) by ($0.01). The firm had revenue of $2.00 million during the quarter, compared to the consensus estimate of $1.90 million. Analysts anticipate that Inhibrx Biosciences, Inc. will post -9.70 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Mark Lappe bought 10,040 shares of the stock in a transaction dated Wednesday, October 14th. The shares were acquired at an average price of $84.56 per share, with a total value of $848,982.40. Following the acquisition, the chief executive officer owned 745,588 shares in the company, valued at $63,046,921.28. This trade represents a 1.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kimberly Manhard sold 500 shares of the firm's stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $110.26, for a total value of $55,130.00. Following the transaction, the director owned 8,000 shares in the company, valued at approximately $882,080. This trade represents a 5.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders purchased 62,540 shares of company stock worth $6,347,507 and sold 1,500 shares worth $168,590. Corporate insiders own 18.26% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INBX. HighTower Advisors LLC grew its holdings in shares of Inhibrx Biosciences by 1.6% during the third quarter. HighTower Advisors LLC now owns 884,441 shares of the company's stock worth $88,515,000 after purchasing an additional 13,890 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Inhibrx Biosciences in the second quarter worth approximately $79,698,000. BlackRock Inc. purchased a new position in Inhibrx Biosciences during the 2nd quarter worth $78,261,000. Parkman Healthcare Partners LLC bought a new position in shares of Inhibrx Biosciences in the second quarter valued at approximately $24,346,000. Finally, Soleus Capital Management L.P. purchased a new position in shares of Inhibrx Biosciences in the 3rd quarter worth about $21,017,000. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company's oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inhibrx Biosciences Right Now?

Before you consider Inhibrx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.

While Inhibrx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines